Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinryze for acute antibody-mediated rejection in kidney transplant
NCT02547220Phase 3Terminated
- Sponsor
- Takeda
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of c1-esterase inhibitor in antibody mediated rejection (AMR), sponsored by Takeda. Started May 2016; status: terminated.
02
Drugs
c1-esterase inhibitor
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02547220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547220.